Synapse

← EJC Paediatric Oncology

Papers in EJC Paediatric Oncology

Page 3 · newest first

  1. Maintenance therapy for pediatric patients with high-risk Rhabdomyosarcoma: A report of dose reductions and dose omissions on outcomeEJC Paediatric Oncology · 2025
  2. European clinical practice recommendations for the diagnosis and treatment of paediatric pineal tumoursEJC Paediatric Oncology · 2025
  3. Parental role in paediatric cancer treatment decision making at Tikur Anbessa Specialized Hospital, Ethiopia: A mixed method studyEJC Paediatric Oncology · 2025
  4. Differences in care delivery for children and adolescents with cancer in Europe – Results from the SIOPE OCEAN projectEJC Paediatric Oncology · 2025
  5. An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcomaEJC Paediatric Oncology · 2025
  6. How to use monoclonal antibody-based therapy in ALLEJC Paediatric Oncology · 2025
  7. The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysisEJC Paediatric Oncology · 2025
  8. Preparedness of European pediatric oncologists to integrate AI in the clinical routineEJC Paediatric Oncology · 2025
  9. Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancerEJC Paediatric Oncology · 2024
  10. European standard clinical practice recommendations for paediatric high-grade gliomasEJC Paediatric Oncology · 2024
  11. Validation of the stratification for newly diagnosed hepatoblastoma: An analysis from the Children’s Hepatic tumors International Collaboration (CHIC) databaseEJC Paediatric Oncology · 2024
  12. Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference NetworkEJC Paediatric Oncology · 2024
  13. KMT2A-rearranged acute lymphoblastic leukaemiaEJC Paediatric Oncology · 2024
  14. Potential of non-FDG PET radiotracers for paediatric patients with solid tumoursEJC Paediatric Oncology · 2024
  15. New insights into hematopoietic cell transplantation in ALL: Who should be transplanted, when, and howEJC Paediatric Oncology · 2024
  16. Enhancing pediatric oncology clinical trials through patient reported outcomes (PROs)EJC Paediatric Oncology · 2024
  17. A practical guide to apply AI in childhood cancer: Data collection and AI model implementationEJC Paediatric Oncology · 2024
  18. General context and relevant public datasets available for improving pathways in Paediatric Cancer applying Artificial Intelligence. A reviewEJC Paediatric Oncology · 2024
  19. Health-related quality of life of toddlers during and after cancer treatmentEJC Paediatric Oncology · 2024
  20. Risk of severe esophageal stricture among childhood cancer survivors – a population-based case-cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS)EJC Paediatric Oncology · 2024
  21. Response to Induction Chemotherapy Modifies the Effect of Conventional Prognostic Factors in High-Risk Neuroblastoma: A Report from the Children’s Oncology Group.EJC Paediatric Oncology · 2024
  22. Approved medicines for paediatric solid tumours in Europe: Lessons from the life cycle of a paediatric investigation planEJC Paediatric Oncology · 2024
  23. Intermittent micafungin dosing schedule in pediatric oncology patients ‐ safe for outpatient parenteral antimicrobial therapy?EJC Paediatric Oncology · 2024
  24. Cross-border access to early phase clinical trials for children with cancer in the Nordic regionEJC Paediatric Oncology · 2024
  25. Clinical use-cases and implementation guidelines for the development of valuable AIEJC Paediatric Oncology · 2024
  26. Multimodality imaging of bone marrow involvement in paediatric oncologyEJC Paediatric Oncology · 2024
  27. Cell state plasticity in neuroblastomaEJC Paediatric Oncology · 2024
  28. Re-irradiation for progressive Diffuse Intrinsic Pontine Glioma (DIPG): The Spanish experienceEJC Paediatric Oncology · 2024
  29. MYCN in neuroblastoma: The kings' new clothes and drugsEJC Paediatric Oncology · 2024
  30. Robotics and 3D modeling for precision surgery in pediatric oncologyEJC Paediatric Oncology · 2024
  31. GD2 targeting CAR T cells for neuroblastomaEJC Paediatric Oncology · 2024
  32. Genetic testing for childhood cancer predisposition syndromes: Controversies and recommendations from the SIOPE Host Genome Working Group meeting 2022EJC Paediatric Oncology · 2024
  33. DNA repair and replicative stress addiction in neuroblastomaEJC Paediatric Oncology · 2024
  34. Environmental risk factors of Wilms tumour: A systematic review and meta-analysisEJC Paediatric Oncology · 2024
  35. Fatigue in patients with hypothalamic syndrome – A cross-sectional analysis of the German childhood-onset craniopharyngioma cohortEJC Paediatric Oncology · 2024
  36. Prophylactic use of liposomal amphotericin B in children and adolescents undergoing allogeneic hematopoietic cell transplantation: A 10-years single center experienceEJC Paediatric Oncology · 2024
  37. Inequities in childhood cancer research: A scoping reviewEJC Paediatric Oncology · 2024
  38. Ophthalmologic adverse events in childhood head and neck rhabdomyosarcoma survivors treated according to four different local treatment strategiesEJC Paediatric Oncology · 2024
  39. European standard clinical practice recommendations for primary pediatric low-grade gliomasEJC Paediatric Oncology · 2024
  40. Impact of ciprofloxacin prophylaxis on blood stream infection during early treatment phase of pediatric acute lymphoblastic leukemia: An observational cohort studyEJC Paediatric Oncology · 2024
  41. Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastomaEJC Paediatric Oncology · 2024
  42. Overview of European standard clinical practice recommendations for multidiscplinary teams involved in the treatment of central nervous system tumours in children and adolescents – SIOPE Brain Tumour GroupEJC Paediatric Oncology · 2024
  43. DICER1 syndrome and its various paediatric presentations: Case series and review of the literatureENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2024
  44. SIOPE and ESOP recommendations for extemporaneous compounding of oral liquid medicine formulations in paediatric oncologyEJC Paediatric Oncology · 2024
  45. Psychological distress in grandparents of grandchildren who survived childhood cancer − Results from the GROkids projectEJC Paediatric Oncology · 2024
  46. The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapiesEJC Paediatric Oncology · 2024
  47. Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)EJC Paediatric Oncology · 2024
  48. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectivesEJC Paediatric Oncology · 2024
  49. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastomaEJC Paediatric Oncology · 2024
  50. Japan’s contribution to an ongoing global pediatric cancer clinical trial: The experience of the National Cancer Center Hospital (NCCH) in TokyoEJC Paediatric Oncology · 2024